- Trials with a EudraCT protocol (44,380)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
44,380 result(s) found.
Displaying page 1,120 of 2,219.
| EudraCT Number: 2012-000812-27 | Sponsor Protocol Number: HEEL-2011-03 | Start Date*: 2012-07-19 | ||||||||||||||||
| Sponsor Name:Radboud University Nijmegen Medical Centre | ||||||||||||||||||
| Full Title: The analgesic efficacy of Δ9-THC (Namisol®) in patients with persistent postsurgical abdominal pain: a randomized, double-blinded, placebo-controlled, parallel design’ | ||||||||||||||||||
| Medical condition: Patients with persistent postsurgical abdominal pain | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: NL (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2013-000639-29 | Sponsor Protocol Number: ABCSG_P00 | Start Date*: 2013-03-27 | ||||||||||||||||
| Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group) | ||||||||||||||||||
| Full Title: A prospective, open, randomized, academic phase II, two-arm trial evaluating the effect of fibrin-coated collagen (TachoSil®) on postoperative pancreatic leakage and fistula formation from the panc... | ||||||||||||||||||
| Medical condition: pancreatic surgery - evaluation of the effect of fibrin-coated collagen | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: AT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2016-002290-35 | Sponsor Protocol Number: MGT006 | Start Date*: 2016-12-20 | |||||||||||
| Sponsor Name:MeiraGTx UK II Limited | |||||||||||||
| Full Title: An open label, multi-centre, Phase I/II dose escalation trial of a recombinant adeno-associated virus vector (AAV2/8-hCARp.hCNGB3) for gene therapy of adults and children with achromatopsia owing t... | |||||||||||||
| Medical condition: Achromatopsia caused by mutations in the CNGB3 gene | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-000038-33 | Sponsor Protocol Number: DF6002-001 | Start Date*: 2021-08-25 |
| Sponsor Name:Dragonfly Therapeutics, Inc. | ||
| Full Title: A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monoth... | ||
| Medical condition: Solid Tumor Melanoma NSCLC Triple-negative breast cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-004634-41 | Sponsor Protocol Number: IIBSP-FPI-2019-108 | Start Date*: 2021-08-25 |
| Sponsor Name:Institut de Recerca HSCSP | ||
| Full Title: Study of the positron emission tomography (PET) tracer for tau 18F-PI-2620 in individuals with Down syndrome | ||
| Medical condition: Taupathies | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-004891-10 | Sponsor Protocol Number: Vocational Rehabilitation | Start Date*: 2007-04-17 | |||||||||||
| Sponsor Name:Charité - Universitätsmedizin Berlin | |||||||||||||
| Full Title: Future strategies for vocational rehabilitation schizophrenia | |||||||||||||
| Medical condition: The social implications and long-term consequences of mental disorders regarding sick days at work, unemployment rates and early retirement are considerable. This trial is being conducted to unders... | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-003999-35 | Sponsor Protocol Number: Kep-F10.2.01 | Start Date*: 2007-01-11 |
| Sponsor Name:Charité Campus Mitte, Klinik für Psychiatrie und Psychotherapie | ||
| Full Title: Efficacy and safety of levetiracetam in prevention of alcohol relapse in recently detoxified alcohol dependent patients | ||
| Medical condition: detoxified alcohol dependent outpatients | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-013432-20 | Sponsor Protocol Number: ISI2009-02 | Start Date*: 2009-08-04 | |||||||||||
| Sponsor Name:Charité Campus Mitte | |||||||||||||
| Full Title: Intra-individual, randomized comparison of the MRI contrast agents gadobutrol versus gadoterate meglumine in breast MR imaging | |||||||||||||
| Medical condition: Breast tumor | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-005710-12 | Sponsor Protocol Number: Ep_Li 001_2006 | Start Date*: 2007-09-28 |
| Sponsor Name:Charité Universitätsmedizin Berlin | ||
| Full Title: Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study) | ||
| Medical condition: Lipoprotein (Lp)(a) has been associated with an increased risk of coronary heart disease, cerebrovascular disease, and peripheral arterial vascular disease. Potential therapies to reduce elevated L... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-001551-22 | Sponsor Protocol Number: RECIPE2014 | Start Date*: 2014-12-18 |
| Sponsor Name:Charité Universitätsmedizin | ||
| Full Title: Reduction of postoperative wound infections by antiseptica | ||
| Medical condition: Laparotomy wound after closure of the fascia after visceral surgery | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2004-000457-34 | Sponsor Protocol Number: FG-506-02-40 | Start Date*: 2004-10-19 | |||||||||||
| Sponsor Name:Fujisawa GmbH | |||||||||||||
| Full Title: A MULTICENTRE, RANDOMISED, OPEN CLINICAL STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINATION THERAPY OF TACROLIMUS WITH SIROLIMUS VERSUS TACROLIMUS WITH MYCOPHENOLATE MOFETIL IN KIDNEY TRANSP... | |||||||||||||
| Medical condition: Patients with end stage kidney disease who will undergo primary renal transplantation or retransplantation. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) AT (Completed) ES (Completed) SE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-000596-34 | Sponsor Protocol Number: WX17798 | Start Date*: 2005-05-19 | |||||||||||
| Sponsor Name:F.Hoffmann-La Roche Ltd. | |||||||||||||
| Full Title: A prospective, randomized, double-blind, placebo controlled, parallel group, multicenter, 36-weeks trial to assess the efficacy and safety of adjunct mycophenolate mofetil (MMF) to maintain or impr... | |||||||||||||
| Medical condition: Myasthenia gravis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) HU (Completed) IT (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-002136-25 | Sponsor Protocol Number: CLAF237A2309E1 | Start Date*: 2005-04-07 |
| Sponsor Name:Novartis Pharmaceuticals UK Ltd | ||
| Full Title: A 52-week extension to a multicenter, randomized, double-blind, active controlled study to compare the effect of 52 weeks treatment with LAF237 50 mg bid to metformin up to 1000 mg bid in drug naïv... | ||
| Medical condition: Type II Diabetes | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2004-002746-35 | Sponsor Protocol Number: D4003C00030 | Start Date*: 2005-07-13 |
| Sponsor Name:AstraZeneca AB | ||
| Full Title: The "EXTEND" study: A randomized, double-blind, parallel-group, phase IIIb, multi-centre study evaluating extended prophylactic treatment with melagatran/ximelagatran versus enoxaparin for the prev... | ||
| Medical condition: Prophylactic treatment for the prevention of venous thromboembolic events in patients undergoing elective hip replacement or hip fracture surgery. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FI (Completed) SE (Completed) HU (Completed) AT (Completed) DK (Completed) DE (Completed) PT (Prematurely Ended) ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2004-001175-19 | Sponsor Protocol Number: 102247 | Start Date*: 2004-08-24 |
| Sponsor Name:GlaxoSmithKline | ||
| Full Title: A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenua... | ||
| Medical condition: Two-dose immunization according to 0, 1 or 2-month schedule against rotavirus disease in healthy infants aged 6 to 14 weeks at the time of the first dose. Rotavirus infection. | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: FI (Completed) CZ (Completed) IT (Completed) ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-000428-18 | Sponsor Protocol Number: SP790 | Start Date*: 2005-06-08 | |||||||||||
| Sponsor Name:Schwarz Biosciences GmbH | |||||||||||||
| Full Title: A mulit-center, randomized, double-blind, placebo-controlled, four-arm parallel group trial to investigate the efficacy and safety of three different transdermal doses of rotigotine in subjects wit... | |||||||||||||
| Medical condition: Restless Leg's Syndrome | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) DE (Completed) GB (Completed) SE (Completed) FI (Completed) ES (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-003290-25 | Sponsor Protocol Number: A1481239 | Start Date*: 2005-12-23 | |||||||||||
| Sponsor Name:Pfizer AB | |||||||||||||
| Full Title: A multicenter, double-blind placebo controlled, fixed dose study with an open-label, flexible dose phase to assess the efficacy of Sildenafil Citrate in providing a better sexual experience includi... | |||||||||||||
| Medical condition: Erectile Dysfunction | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male | ||||||||||||
| Trial protocol: SE (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-000039-73 | Sponsor Protocol Number: CSPP100A2327 | Start Date*: 2005-07-18 |
| Sponsor Name:Novartis Pharma Services AG | ||
| Full Title: An 8-week randomized, double-blind, parallel group, multi-center, placebo and active controlled dose escalation study to evaluate the efficacy and safety of aliskiren (150 mg and 300 mg) administer... | ||
| Medical condition: Hypertension | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2004-000354-22 | Sponsor Protocol Number: A3841029 | Start Date*: 2004-12-06 |
| Sponsor Name:Pfizer Healthcare Ireland | ||
| Full Title: An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine –Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL II Study) | ||
| Medical condition: Concurrent hypertension (ICD code 80011/MedDRA: coded under preferred term "vascular system order", code 10020772) and dyslipidaemia (ICD code 89212/MedDRA: coded under preferred term "metabolism a... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: IE (Completed) ES (Completed) AT (Completed) HU (Completed) IT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2004-000774-31 | Sponsor Protocol Number: E7070-E044-213 | Start Date*: 2005-10-12 | |||||||||||
| Sponsor Name:Eisai Limited | |||||||||||||
| Full Title: An open-label, randomized phase II study of the efficacy and safety of indisulam (E7070) in combination with capecitabine versus capecitabine monotherapy for the treatment of metastatic breast can... | |||||||||||||
| Medical condition: Treatment of metastatic breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: GB (Completed) DE (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.